新冠肺炎初期对症药物治疗建议
Rational Drug Usage Suggestion for COVID-19 Patients at Prime Stage
DOI: 10.12677/PI.2020.95027, PDF,   
作者: 杨谨成, 范琳琳, 王忠革, 陈莲珍*:国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院药剂科,北京
关键词: 新冠肺炎感冒流行性感冒对症治疗抗病毒药COVID-19 Cold Flu Symptomatic Treatment Antiviral Drug
摘要: 新型冠状病毒感染肺炎的中文命名为“新冠肺炎”(“新型冠状病毒肺炎”),英文名为COVID-19 (Corona Virus Disease-19)。目前有专家和部分事实证明新冠肺炎可能是自限性疾病。在疾病初期,特别是轻症患者,新冠肺炎和普通感冒症状有相似之处。我们建议可以像治疗普通感冒或者流行性感冒用相应的药物尽早对症治疗,同时采取尽早隔离的措施,加强营养和增加免疫力,必要时审慎选用相对有效的抗病毒药;减少疾病发展到中重度的几率,节约有限的医疗资源。
Abstract: Corona Virus Disease is named as NCP (Novel Coronavirus Pneumonia) in Chinese, and COVID-19 (Corona Virus Disease-19) internationally. Currently, specialists and some facts indicated COVID-19 might be self-limited disease. At prime stage, especially for mild performance, there are many similarities between COVID-19 and common cough. We suggest patients take medicine for symptomatic treatment as common cold or Flu and take isolation as early as possible, select corresponding antiviral drug prudently, and meanwhile, give strong nutrition support, enough rest, optimism as well as physical exercise to diminish probability of developing disease into moderate or severe stages for saving limited medical resource.
文章引用:杨谨成, 范琳琳, 王忠革, 陈莲珍. 新冠肺炎初期对症药物治疗建议[J]. 药物资讯, 2020, 9(5): 181-185. https://doi.org/10.12677/PI.2020.95027

参考文献

[1] 国家卫健委官网[Z]. http://www.nhc.gov.cn/
[2] 世界卫生组织官网[Z].
https://www.who.int
[3] 巩玥, 史志祥, 陈菁, 等. 冠状病毒的研究现状[J]. 中国生物工程杂志, 2020, 40(Z1): 1-20.
[4] 中国疾病预防控制中心新型冠状病毒感染的肺炎疫情一级响应态势分析与风险评估组. 2019新型冠状病毒疫情进展和风险评估[Z]. 2020.
[5] 国家卫健委办公厅. 新型冠状病毒感染的肺炎诊疗方案(试行第七版) [S]. 2020.
[6] Huang, C.L., Wang, Y.M., Li., X.W., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet, 395, 497-506. [Google Scholar] [CrossRef
[7] 叶陈伟. 抗感冒药物成分的药理特征及其临床用药分析[J]. 临床合理用药杂志, 2016, 9(6C): 171-172.
[8] 庞文渊, 王乔羽, 赵志刚. 新型冠状病毒肺炎的药物治疗方案及研究进展[J]. 临床药物治疗杂志, 2020(2): 24-29.
[9] Cao, B., Wang, Y., Wen, D., et al. (2020) A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. The New England Journal of Medicin, 382, 1787-1799. [Google Scholar] [CrossRef
[10] Dong, L.Y., Hu, S.S. and Gao, J.J. (2020) Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19). Drug Discoveries & Therapeutics, 14, 58-60. [Google Scholar] [CrossRef] [PubMed]
[11] Gautret, P., Lagier, J.-C., Parola, P., et al. (2020) Hy-droxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial. International Journal of Antimicrobial Agents, 56, Article ID: 105949. [Google Scholar] [CrossRef] [PubMed]
[12] 凌云, 狄亚敏, 陆青青, 等. 流行性感冒的病原学特征及其药物治疗进展[J]. 解放军药学学报, 2018, 34(2): 63-68.
[13] 冯修武. 上呼吸道感染中微生态制剂的功效研究[J]. 临床医药文献电子杂志, 2015(7): 1228-1229.
[14] 于恺英, 石汉平. 《关于新型冠状病毒肺炎患者的医学营养治疗专家建议》解读[J]. 中华医学杂志, 2020(100): E005.